489 related articles for article (PubMed ID: 34918477)
1. A year in heart failure: an update of recent findings.
Stretti L; Zippo D; Coats AJS; Anker MS; von Haehling S; Metra M; Tomasoni D
ESC Heart Fail; 2021 Dec; 8(6):4370-4393. PubMed ID: 34918477
[TBL] [Abstract][Full Text] [Related]
2. The year in cardiovascular medicine 2021: heart failure and cardiomyopathies.
Bauersachs J; de Boer RA; Lindenfeld J; Bozkurt B
Eur Heart J; 2022 Feb; 43(5):367-376. PubMed ID: 34974611
[TBL] [Abstract][Full Text] [Related]
3. Heart failure: an update from the last years and a look at the near future.
Riccardi M; Sammartino AM; Piepoli M; Adamo M; Pagnesi M; Rosano G; Metra M; von Haehling S; Tomasoni D
ESC Heart Fail; 2022 Dec; 9(6):3667-3693. PubMed ID: 36546712
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update.
Hellenkamp K; Nolte K; von Haehling S
Expert Opin Pharmacother; 2022 Apr; 23(6):673-680. PubMed ID: 35260016
[TBL] [Abstract][Full Text] [Related]
5. The Heart Failure Knights.
Mozzini C; Pagani M
Curr Probl Cardiol; 2023 Sep; 48(9):101834. PubMed ID: 37244515
[TBL] [Abstract][Full Text] [Related]
6. Consensus statement on the current pharmacological prevention and management of heart failure.
Sindone AP; De Pasquale C; Amerena J; Burdeniuk C; Chan A; Coats A; Hare DL; Macdonald P; Sverdlov A; Atherton JJ
Med J Aust; 2022 Aug; 217(4):212-217. PubMed ID: 35908234
[TBL] [Abstract][Full Text] [Related]
7. Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?
Ameri P; Bertero E; Maack C; Teerlink JR; Rosano G; Metra M
Eur Heart J Cardiovasc Pharmacother; 2021 Nov; 7(6):539-546. PubMed ID: 34037742
[TBL] [Abstract][Full Text] [Related]
8. Advances in contemporary medical management to treat patients with heart failure.
Velez M
Curr Opin Cardiol; 2023 Mar; 38(2):136-142. PubMed ID: 36718623
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines.
Tsutsui H
Pharmacol Ther; 2022 Oct; 238():108185. PubMed ID: 35413307
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
[TBL] [Abstract][Full Text] [Related]
11. Heart failure in the last year: progress and perspective.
Tomasoni D; Adamo M; Anker MS; von Haehling S; Coats AJS; Metra M
ESC Heart Fail; 2020 Dec; 7(6):3505-3530. PubMed ID: 33277825
[TBL] [Abstract][Full Text] [Related]
12. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology.
Mullens W; Martens P; Testani JM; Tang WHW; Skouri H; Verbrugge FH; Fudim M; Iacoviello M; Franke J; Flammer AJ; Palazzuoli A; Barragan PM; Thum T; Marcos MC; Miró Ò; Rossignol P; Metra M; Lassus J; Orso F; Jankowska EA; Chioncel O; Milicic D; Hill L; Seferovic P; Rosano G; Coats A; Damman K
Eur J Heart Fail; 2022 Apr; 24(4):603-619. PubMed ID: 35239201
[TBL] [Abstract][Full Text] [Related]
13. Patient Eligibility for Established and Novel Guideline-Directed Medical Therapies After Acute Heart Failure Hospitalization.
Moghaddam N; Hawkins NM; McKelvie R; Poon S; Joncas SX; MacFadyen J; Honos G; Wang J; Rojas-Fernandez C; Kok M; Sidhu V; Zieroth S; Virani SA
JACC Heart Fail; 2023 May; 11(5):596-606. PubMed ID: 36732099
[TBL] [Abstract][Full Text] [Related]
14. Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial.
Rosano G; Ponikowski P; Vitale C; Anker SD; Butler J; Fabien V; Filippatos G; Kirwan BA; Macdougall IC; Metra M; Ruschitzka F; Kumpeson V; Goehring UM; van der Meer P; Jankowska EA;
Cardiovasc Diabetol; 2023 Aug; 22(1):215. PubMed ID: 37592272
[TBL] [Abstract][Full Text] [Related]
15. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
16. Current Updates in the Pharmacotherapy of Heart Failure with a Preserved Ejection Fraction.
Dahal R; Nickel N; Mukherjee D; Alkhateeb H
Cardiovasc Hematol Disord Drug Targets; 2022; 22(2):87-95. PubMed ID: 35786196
[TBL] [Abstract][Full Text] [Related]
17. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.
Senni M; Gavazzi A; Oliva F; Mortara A; Urso R; Pozzoli M; Metra M; Lucci D; Gonzini L; Cirrincione V; Montagna L; Di Lenarda A; Maggioni AP; Tavazzi L;
Int J Cardiol; 2014 May; 173(2):163-9. PubMed ID: 24630337
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta-analysis.
Anker SD; Khan MS; Butler J; von Haehling S; Jankowska EA; Ponikowski P; Friede T
Eur J Heart Fail; 2023 Jul; 25(7):1080-1090. PubMed ID: 37062867
[TBL] [Abstract][Full Text] [Related]
19. Advances in the Management of Heart Failure with Reduced Ejection Fraction; The Role of SGLT2is, ARNI, Myotropes, Vericiguat, and Anti-inflammatory Agents: A Mini-review.
Vrachatis DA; Papathanasiou KA; Giotaki SG; Raisakis K; Kaoukis A; Kossyvakis C; Theodorakis A; Pediotidis S; Avramides D; Siasos G; Deftereos S
Curr Pharm Des; 2023 Mar; ():. PubMed ID: 36927423
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
